Hormonal contraception and thrombosis

Authors’ reply to Costescu and Waddington

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2369 (Published 16 April 2013)
Cite this as: BMJ 2013;346:f2369

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Frits R Rosendaal, professor in clinical epidemiology1,
  2. Frans M Helmerhorst, professor in clinical epidemiology of fertility1
  1. 1Leiden University Medical Center, 2300 RC Leiden, Netherlands
  1. F.R.Rosendaal{at}lumc.nl

Costescu and Waddington think that there is no reason for a European Medicines Agency review or any concern because oral contraceptives containing third generation progestogens, drospirenone, and cyprotereone acetate are all equally safe.1 2

Their main point is that all retrospective studies are fraught with bias. Undoubtedly, any study can be biased—we dealt with this point more than …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL